GlobeNewswire by notified

Pandora Trading Update for February 2021

Share

Pandora today releases a trading update for February 2021. The trading update is, as the January trading update, released as a press release, and not a company announcement, per instructions from NASDAQ Copenhagen.

Pandora has previously communicated that the company would, when relevant, release extraordinary trading updates due to the elevated uncertainty related to COVID-19. During February, the number of stores closed due to COVID-19 decreased from around 30% at the beginning of the month to around 25% by the end of the month.

In February, the organic growth was 12% and total sell-out growth was 7% compared to February 2020. This translates into a quarter to date organic growth of 4% and total sell-out growth of 1%. Compared to February 2019, organic growth was 10% and total sell-out growth was -2% (quarter to date 5% and -6% respectively).

Pandora is pleased with the performance so far in 2021. Considering that 25-30% of the stores were closed during January and February, the underlying trading continues to indicate that sell-out is stabilizing or growing. Sell-out growth in the US continues to be very strong.  

Pandora maintains its financial guidance for 2021: Organic growth “Above 8%” and EBIT margin “Above 21%”.  

ABOUT PANDORA
Pandora designs, manufactures and markets hand-finished jewellery made from high-quality materials at affordable prices. Pandora jewellery is sold in more than 100 countries through more than 7,000 points of sale, including around 2,700 concept stores.​

Headquartered in Copenhagen, Denmark, Pandora employs 26,000 people worldwide and crafts its jewellery at two LEED certified facilities in Thailand using mainly recycled silver and gold. The company plans to be carbon neutral by 2025 and has joined the Science Based Targets initiative to reduce emissions across its full value chain. Pandora is listed on the Nasdaq Copenhagen stock exchange and generated sales of DKK 19.0 billion (EUR 2.5 billion) in 2020.

CONTACT

INVESTOR RELATIONS
John Bäckman
VP, Investor Relations, Tax & Treasury
+45 5356 6909
jobck@pandora.net


Kristoffer Aas Malmgren
Investor Relations Director
+45 3050 1174
kram@pandora.net
CORPORATE COMMUNICATIONS
Johan Melchior
Director External Relations
+45 4060 1415
jome@pandora.net

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Weekly share repurchase program transaction details8.5.2024 18:41:09 CEST | Press release

May 8, 2024 SBM Offshore reports the transaction details related to its EUR65 million (c. US$70 million) share repurchase program for the period May 2, 2024 through May 8, 2024. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024 and effective from March 1, 2024. The objective of the program is to reduce share capital. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period March 1, 2024 through May 8, 2024 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase ProgramOverall progress Share Repurchase Program: Total Repurchase Amount EUR 65,000,000 Cumulative Repurchase Amount EUR 15,064,569 Cumulative Quantity Repurchased 1,059,438 Cumulative

Q3 2023/24 - First sale of the XM30 completed8.5.2024 18:20:00 CEST | Press release

ANNOUNCEMENT NO. 262 Trading statement for Q3 2023/24 (1 January - 31 March 2024) First sale of the XM30 completed Revenue declined by 6% in the third quarter of 2023/24 to DKK 98.9 million from DKK 105.4 million in the year-earlier period. The development reflected continued growth in sales of consumables and services, set off by declining sales of instruments as customers continued to show restraint in purchasing new instruments. EBITDA fell to DKK 43.1 million in the third quarter, being affected by higher staff costs, including non-recurring costs in connection with organisational changes. The EBITDA margin was 44%. In the third quarter, our two new products, the XcytoMatic 40 (XM40) and the XcytoMatic 30 (XM30) attracted satisfactory customer interest, and the first sale of the XM30 was completed. 2023/24Q3Q1-Q3Change, %Change, %Revenue, DKKm98.9-6298.2-14EBITDA, DKKm43.1-23136.2-32EBITDA margin (%)4446 Highlights Revenue declined by 6% in the third quarter of 2023/24 to DKK 98.9

3. kvartal 2023/24 - Første salg af XM30 er gennemført8.5.2024 18:20:00 CEST | pressemeddelelse

MEDDELELSE NR. 262 Periodemeddelelse for 3. kvartal 2023/24 (1. januar - 31. marts 2024) Første salg af XM30 er gennemført Omsætningen faldt i 3. kvartal med 6% til DKK 98,9 mio. mod DKK 105,4 mio. i samme periode sidste år. Udviklingen afspejler en fortsat fremgang i salget af forbrugsvarer og services, mens omsætningen af instrumenter har været faldende som følge af kundernes fortsatte tilbageholdenhed med at købe nye instrumenter. Resultatet af primær drift (EBITDA) faldt i 3. kvartal til DKK 43,1 mio. og var påvirket af øgede personaleomkostninger, herunder engangsomkostninger i forbindelse med organisationsændringer. EBITDA-marginen blev i 3. kvartal på 44%. I 3. kvartal har der været en tilfredsstillende interesse for de to nye produkter, XcytoMatic 40 (XM40) og XcytoMatic 30 (XM30), og det første salg af XM30 er gennemført. 2023/243. kvartal1.-3. kvartalÆndring, %Ændring, %Omsætning, DKK mio.98,9-6298,2-14EBITDA, DKK mio.43,1-23136,2-32EBITDA-margin, %4446 Hovedpunkter Omsætning

International Petroleum Corporation Announces 2024 Annual General Meeting Voting Results8.5.2024 18:00:00 CEST | Press release

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce the voting results from the Corporation’s 2024 Annual General Meeting of Shareholders held on May 8, 2024 in Calgary, Alberta (the Meeting). Number of Directors The number of Directors of the Corporation was set at eight. Votes For% ForVotes Against% Against62,674,77899.995,3870.01 Election of Directors The eight nominees listed in the Corporation’s management information circular dated March 22, 2024 (the Circular) were elected as Directors of the Corporation to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed, unless the office is earlier vacated, as described in the Circular. NomineeVotes For% ForVotes Withheld% WithheldC. Ashley Heppenstall61,390,66198.101,187,5871.90William Lundin62,290,86899.54287,3800.46Chris Bruijnzeels62,177,25599.36400,9930.64Donald Charter55,737,08589.076,841,16310.93Lukas H. (Harry

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons8.5.2024 17:31:01 CEST | Press release

Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar2 Reason for the notificationa)Position/statusExecutive Vice Presidentb)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN342

HiddenA line styled icon from Orion Icon Library.Eye